News

AV-203 is an ErbB3 (HER3)-targeted antibody, which belongs to a family of four proteins that also includes the epidermal growth factor receptor (EGFR) and the HER2 receptor. Laureate’s

Sangamo posted a net loss of $8.7m for the third quarter 2010, or $0.19 per diluted share, compared to net loss of $4.85m, or $0.12 per diluted share,

Vesicare OD, a muscarine receptor antagonist discovered and developed by Astellas, was approved for an additional formulation of the overactive bladder treatment with the indication of urinary frequency,

Omnicell has posted a net income of $1.28m for the third quarter 2010, or $0.04 per diluted share, compared to $854,000m, or $0.03 per diluted share, for the

PPD posted a net income of $38m for the third quarter 2010, or $0.33 per diluted share, compared to $37.67m, or $0.34 per diluted share, for the comparable

The partnership will provide integration of technologies and processes, giving biopharmaceutical companies near real-time, consistent and reliable medical imaging information to expedite their drug development programs. The integration

The sponsored research agreement will support the analysis of miRNA and gene expression changes from a study conducted at the University of Colorado Cardiovascular Institute at the UC

Under the terms of the option agreement, Celtic Therapeutics has an exclusive option to acquire and license rights to Resolvyx’s RX-10045, in all eye indications. RX-10045 is scheduled

TMX-67, an oral, once-daily, highly potent, non-purine selective inhibitor of xanthine oxidase, with a structure different from allopurinol, lowers the level of uric acid in the blood of